InMode (INMD) EBIT Margin (2018 - 2026)

InMode (INMD) posted EBIT Margin of 12.26% for Q1 2026, down 51.01% sequentially from 25.03% in Q4 2025, and down 779.0% YoY from 1.81% in Q1 2025.

InMode (INMD) EBIT Margin (2018 - 2026) Analysis & Trends

InMode has reported EBIT Margin for 9 years, with the latest figure at 12.26% in Q1 2026.

Quarterly EBIT Margin fell 779.0% year-over-year to 12.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.31% (down 674.0% YoY) and the FY2025 annual result came in at 23.05%, down 546.0% from the prior year.
EBIT Margin eased to 12.26% in Q1 2026 per INMD's latest filing, from 25.03% in the prior quarter.
Over five years, EBIT Margin peaked at 46.67% in Q2 2023 and troughed at 12.26% in Q1 2026.
A 5-year average of 32.33% and a median of 37.06% in 2024 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2023 and 2024: EBIT Margin surged 334 bps in 2023, then sank 2549 bps in 2024.
Over 5 years, EBIT Margin stood at 44.84% in 2022, then declined by 10 bps to 40.42% in 2023, then dropped by 30 bps to 28.48% in 2024, then slipped by 12 bps to 25.03% in 2025, then slumped by 51 bps to 12.26% in 2026.
According to Business Quant data, EBIT Margin over the past three periods registered 12.26%, 25.03%, and 22.43% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	13.44%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	25.18%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	19.10%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	21.65%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	29.48%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	24.33%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	13.96%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	10.30%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	19.15%
10	InMode	912.51 Mn	497.35 Mn	71.52 Mn	12.82%

Download Data